211 related articles for article (PubMed ID: 20570888)
21. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.
Kobori H; Hashiguchi M; Piao J; Kato M; Ritprajak P; Azuma M
Immunology; 2010 Jul; 130(3):363-73. PubMed ID: 20141543
[TBL] [Abstract][Full Text] [Related]
22. Targeted siRNA silencing of indoleamine 2, 3-dioxygenase in antigen-presenting cells using mannose-conjugated liposomes: a novel strategy for treatment of melanoma.
Chen D; Koropatnick J; Jiang N; Zheng X; Zhang X; Wang H; Yuan K; Siu KS; Shunnar A; Way C; Min WP
J Immunother; 2014; 37(2):123-34. PubMed ID: 24509175
[TBL] [Abstract][Full Text] [Related]
23. Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans.
Shikano S; Bonkobara M; Zukas PK; Ariizumi K
J Biol Chem; 2001 Mar; 276(11):8125-34. PubMed ID: 11114299
[TBL] [Abstract][Full Text] [Related]
24. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
[TBL] [Abstract][Full Text] [Related]
25. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
26. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells.
Chen Z; Moyana T; Saxena A; Warrington R; Jia Z; Xiang J
Int J Cancer; 2001 Aug; 93(4):539-48. PubMed ID: 11477558
[TBL] [Abstract][Full Text] [Related]
27. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
28. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
[TBL] [Abstract][Full Text] [Related]
29. The non-classical MHC class I molecule Qa-1(b) inhibits classical MHC class I-restricted cytotoxicity of cytotoxic T lymphocytes.
Lohwasser S; Kubota A; Salcedo M; Lian RH; Takei F
Int Immunol; 2001 Mar; 13(3):321-7. PubMed ID: 11222501
[TBL] [Abstract][Full Text] [Related]
30. T-cell receptor gene therapy of established tumors in a murine melanoma model.
Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
[TBL] [Abstract][Full Text] [Related]
31. mRNA expression of the murine glycoprotein (transmembrane) nmb (Gpnmb) gene is linked to the developing retinal pigment epithelium and iris.
Bächner D; Schröder D; Gross G
Brain Res Gene Expr Patterns; 2002 Oct; 1(3-4):159-65. PubMed ID: 12638126
[TBL] [Abstract][Full Text] [Related]
32. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
[TBL] [Abstract][Full Text] [Related]
33. Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.
Touloukian CE; Leitner WW; Schnur RE; Robbins PF; Li Y; Southwood S; Sette A; Rosenberg SA; Restifo NP
J Immunol; 2003 Feb; 170(3):1579-85. PubMed ID: 12538723
[TBL] [Abstract][Full Text] [Related]
34. Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity.
Matsushita N; Komine H; Grolleau-Julius A; Pilon-Thomas S; Mulé JJ
Cancer Immunol Immunother; 2010 Jun; 59(6):875-84. PubMed ID: 20054688
[TBL] [Abstract][Full Text] [Related]
35. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine.
Leitch J; Fraser K; Lane C; Putzu K; Adema GJ; Zhang QJ; Jefferies WA; Bramson JL; Wan Y
J Immunol; 2004 May; 172(9):5200-5. PubMed ID: 15100257
[TBL] [Abstract][Full Text] [Related]
36. Paired immunoglobin-like receptors A and B are new targets for inducing dendritic cells tolerance in mice.
Liu Z; Li W; Zhang M; Zhou H; Han H; Zou P
J Huazhong Univ Sci Technolog Med Sci; 2007 Jun; 27(3):252-6. PubMed ID: 17641835
[TBL] [Abstract][Full Text] [Related]
37. In vivo knockdown of CXCR4 using jetPEI/CXCR4 shRNA nanoparticles inhibits the pulmonary metastatic potential of B16‑F10 melanoma cells.
André ND; Silva VA; Ariza CB; Watanabe MA; De Lucca FL
Mol Med Rep; 2015 Dec; 12(6):8320-6. PubMed ID: 26498029
[TBL] [Abstract][Full Text] [Related]
38. The transcription factor RBP-J-mediated signaling is essential for dendritic cells to evoke efficient anti-tumor immune responses in mice.
Feng F; Wang YC; Hu XB; Liu XW; Ji G; Chen YR; Wang L; He F; Dou GR; Liang L; Zhang HW; Han H
Mol Cancer; 2010 Apr; 9():90. PubMed ID: 20420708
[TBL] [Abstract][Full Text] [Related]
39. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
Palmer DC; Balasubramaniam S; Hanada K; Wrzesinski C; Yu Z; Farid S; Theoret MR; Hwang LN; Klebanoff CA; Gattinoni L; Goldstein AL; Yang JC; Restifo NP
J Immunol; 2004 Dec; 173(12):7209-16. PubMed ID: 15585842
[TBL] [Abstract][Full Text] [Related]
40. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
